Genentech, Inc.

This early-stage trial tests a new drug called runimotamab, alone or with trastuzumab, in 123 people with advanced HER2-positive cancers. The main goal is to check safety and how the drug moves through the body. It is for patients whose cancer has spread or cannot be removed by s…

This study offers continued treatment with trastuzumab emtansine (Kadcyla), alone or with other drugs, to 720 patients with metastatic cancer who were already benefiting from it in a previous trial. The main goal is to monitor long-term safety and side effects. It is an open-labe…

This phase 2 trial is testing whether adding venetoclax to standard BTK inhibitor therapy can help people with chronic lymphocytic leukemia (CLL) achieve very deep remission. The goal is to see if patients can then safely stop all treatment for a period. The study involves 118 ad…

This study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…

This early-phase study tests a new drug called GDC-9545, alone or with other medicines, in people with advanced or spreading ER-positive/HER2-negative breast cancer. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 181 pa…

This study tests an experimental drug called RO7446603, given alone or with existing medications (aflibercept or faricimab), for people with diabetic macular edema—a condition that causes vision loss due to diabetes. The trial has two parts: an early safety phase (Phase I) and a …

This phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with certain types of non-Hodgkin lymphoma. The study includes 320 participants and aims to see if the drug can shrink tumors or delay cancer growth. Researchers are also checking for…

This study follows about 400 adults and children with spinal muscular atrophy who are taking risdiplam (Evrysdi) to see how safe and effective it is over roughly two years. Researchers will track side effects and any changes in participants' health. The goal is to better understa…

This early-stage trial tests a new drug called cevostamab, alone or with other medicines, in people whose multiple myeloma has returned or stopped responding to treatment. About 126 participants will receive the drug through an IV to see if it is safe and what dose works best. Th…

This early-phase study tests a new drug (XmAb24306) combined with another drug (cevostamab) in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to check safety and find the right dose. About 90 participants…

This early-stage study tests a new medicine (RO7497372) given as an eye injection for people with diabetic macular edema, a condition that causes blurred vision. The main goal is to check safety and how the drug moves through the body. About 151 participants will receive either a…

This early-stage study tests an experimental cell therapy called P-CD19CD20-ALLO1 in 60 adults with multiple sclerosis. The main goal is to see if it is safe and how the body handles it. Researchers will also measure how long the cells last and how they affect the immune system.

This study tests a new drug, giredestrant, combined with everolimus against standard hormone therapy plus everolimus in people with a common type of advanced breast cancer (ER+/HER2-). About 373 participants who have already tried other treatments will be enrolled. The goal is to…

This early-stage study tests a new drug called belvarafenib, alone or with other drugs (cobimetinib and nivolumab), in people with advanced melanoma that has a specific NRAS gene change and has stopped responding to standard immunotherapy. The main goals are to check safety and f…

This early-phase study tests a new drug called inavolisib in people with advanced solid tumors or breast cancer that have a specific PIK3CA gene mutation. The study aims to find a safe dose and see how well the drug works alone or with other cancer treatments. About 200 participa…

This early-stage study tests a new drug (RO7496353) combined with an immunotherapy (checkpoint inhibitor) and sometimes chemotherapy in people with advanced lung, stomach, or pancreatic cancer. The main goal is to check safety and find the right dose. About 102 participants will …

This early-phase study tests a new drug, GDC-6036, in people with advanced cancers (like lung or colorectal) that have a specific KRAS G12C mutation. The goal is to check safety and find the right dose, both when used alone and with other cancer drugs. About 498 participants will…

This study looks at how well the eye medicine faricimab works in people with diabetic macular edema who have not been treated before. It focuses on Black, Hispanic, Native American, and Asian Indian patients, who are often underrepresented in research. About 218 adults will recei…

This study follows 400 people with intermediate age-related macular degeneration (AMD) for about 3 years. Researchers watch how the disease advances to more severe stages and test if measuring the loss of light-sensing cells in the eye can be a useful way to track the disease. No…

This study checks if two different devices for injecting trastuzumab under the skin work the same way in the body. It involves 312 healthy men who will get a single dose. The goal is to see if the drug levels are similar, not to treat any disease.